Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
OS Therapies Incorporated (OSTX)
USD1.55
-0.11 (-6.63%)
US AMEX Healthcare Biotechnology
Address
115 Pullman Crossing Road 21638
Grasonville, MD, US
Grasonville, MD, US
CEO
Paul A. Romness
Website
ostherapies.com
IPO
2024-08-01
CIK 1795091 ISIN US68764Y2072
Description
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.55
-0.11 (-6.63%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
778.7K
Beta
-0.95
Float Shares
23.97M
Free Float %
57.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.98% | +0.58% | +24.46% | +47.86% | +0.00% | +23.57% | +8.81% | -31.08% | -31.08% | -31.08% | -31.08% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
1.55
DCF (Unlevered)
8.90
+474.2%
DCF (Levered)
9.22
+495.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-24.83
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-88.5% Q1'26: -50.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+40.2% Q1'26: +82.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 205.5K (-100.0%)
|
—
est: 36.67M (-100.0%)
|
5.56M
4.93M – 5.95M
-84.8% YoY
|
28.03M
27.46M – 28.59M
+403.9% YoY
|
44.83M
44.83M – 44.83M
+59.9% YoY
|
68.99M
61.17M – 73.81M
+53.9% YoY
|
186.50M
165.36M – 199.52M
+170.3% YoY
|
| EBITDA |
-6.83M
|
-28.39M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-6.83M
|
-28.75M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-8.88M
est: -30.32M (+70.7%)
|
-28.75M
est: -20.05M (-43.4%)
|
-8.27M
-103.68M – 69.46M
+58.8% YoY
|
-8.52M
-13.79M – 3.94M
-3.0% YoY
|
-1.22M
-2.63M – 3.95M
+85.7% YoY
|
3.51M
2.99M – 3.83M
+387.8% YoY
|
50.83M
43.34M – 55.44M
+1,347.9% YoY
|
| SGA |
3.97M
|
12.34B
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.52
est: -1.07 (+51.3%)
|
-0.98
est: -0.69 (-42.0%)
|
-0.60
-3.54 – 2.37
+12.7% YoY
|
-0.20
-0.47 – 0.13
+66.5% YoY
|
-0.02
-0.09 – 0.14
+92.6% YoY
|
0.12
0.10 – 0.13
+900.0% YoY
|
1.74
1.48 – 1.90
+1,347.9% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-30 | D. Boral Capital | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
12
Total invested
2.36M
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
12
-12 vs prev Q
New positions
7
Closed positions
19
Increased
8
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 540.4K +352.2K (+187.1%) | 756.6K +387.6K (+105.0%) | 1.69% +1.102 pp | 0.00% +0.000 pp | USD1.60 -12.5% | 2 qtrs — |
| 2 | CM MANAGEMENT, LLC | 400.0K +— (+0.0%) | 560.0K -224.0K (-28.6%) | 1.25% +0.000 pp | 0.47% -0.182 pp | USD2.20 -36.4% | 6 qtrs — |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 246.0K +58.4K (+31.1%) | 344.5K -23.4K (-6.4%) | 0.77% +0.183 pp | 0.00% +0.000 pp | USD1.83 -23.5% | 2 qtrs — |
| 4 | MARSHALL WACE, LLP | 109.9K -88.6K (-44.6%) | 153.9K -235.2K (-60.4%) | 0.34% -0.277 pp | 0.00% 0.000 pp | USD1.96 -28.6% | 2 qtrs — |
| 5 | TWO SIGMA INVESTMENTS, LP | 87.5K +1.3K (+1.5%) | 122.6K -46.5K (-27.5%) | 0.27% +0.004 pp | 0.00% 0.000 pp | USD1.95 -28.2% | 2 qtrs — |
| 6 | NORTHERN TRUST CORP | 71.3K +15.0K (+26.7%) | 99.8K -10.4K (-9.5%) | 0.22% +0.047 pp | 0.00% +0.000 pp | USD1.84 -23.9% | 2 qtrs — |
| 7 | BLACKROCK, INC. | 61.4K +13.3K (+27.5%) | 86.0K -8.4K (-8.9%) | 0.19% +0.042 pp | 0.00% +0.000 pp | USD1.75 -20.0% | 5 qtrs — |
| 8 | STATE STREET CORP | 58.5K +8.2K (+16.3%) | 81.9K -16.7K (-16.9%) | 0.18% +0.026 pp | 0.00% +0.000 pp | USD1.88 -25.5% | 2 qtrs — |
| 9 | INGALLS & SNYDER LLC | 36.7K +— (+0.0%) | 51.0K -21.0K (-29.2%) | 0.11% +0.000 pp | 0.00% -0.001 pp | USD1.54 -9.1% | 4 qtrs — |
| 10 | MILLENNIUM MANAGEMENT LLC | 30.8K -62.8K (-67.1%) | 43.1K -140.3K (-76.5%) | 0.10% -0.197 pp | 0.00% 0.000 pp | USD1.96 -28.6% | 2 qtrs — |
| 11 | JANE STREET GROUP, LLC | 27.7K +27.7K (+100.0%) | 38.8K +38.8K (+100.0%) | 0.09% +0.087 pp | 0.00% +0.000 pp | USD1.40 +0.0% | 1 qtrs NEW |
| 12 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 25.0K +— (+0.0%) | 35.0K -14.0K (-28.6%) | 0.08% +0.000 pp | 0.00% 0.000 pp | USD1.88 -25.5% | 3 qtrs — |
| 13 | UBS GROUP AG | 18.2K +17.9K (+7,898.2%) | 25.4K +25.0K (+5,611.9%) | 0.06% +0.056 pp | 0.00% +0.000 pp | USD1.41 -0.7% | 3 qtrs — |
| 14 | STIFEL FINANCIAL CORP | 15.0K +— (+0.0%) | 21.0K -8.4K (-28.6%) | 0.05% +0.000 pp | 0.00% +0.000 pp | USD1.54 -9.1% | 4 qtrs — |
| 15 | STRATOS WEALTH ADVISORS, LLC | 13.8K +13.8K (+100.0%) | 19.3K +19.3K (+100.0%) | 0.04% +0.043 pp | 0.00% +0.001 pp | USD1.40 +0.0% | 1 qtrs NEW |
| 16 | JONES FINANCIAL COMPANIES LLLP | 10.9K +3.0K (+38.1%) | 15.2K -913.0 (-5.7%) | 0.03% +0.009 pp | 0.00% +0.000 pp | USD1.81 -22.7% | 2 qtrs — |
| 17 | MERCER GLOBAL ADVISORS INC /ADV | 10.2K -10.2K (-50.0%) | 14.3K -25.8K (-64.3%) | 0.03% -0.032 pp | 0.00% +0.000 pp | USD1.96 -28.6% | 2 qtrs — |
| 18 | LPL FINANCIAL LLC | 10.1K +10.1K (+100.0%) | 14.2K +14.2K (+100.0%) | 0.03% +0.032 pp | 0.00% +0.000 pp | USD1.40 +0.0% | 1 qtrs NEW |
| 19 | MORGAN STANLEY | 1.0K +— (+0.0%) | 1.4K -560.0 (-28.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.91 -26.7% | 5 qtrs — |
| 20 | ROYAL BANK OF CANADA | 480.00 +480.0 (+100.0%) | 1.0K +1.0K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD1.40 +0.0% | 1 qtrs NEW |
| 21 | ARMSTRONG ADVISORY GROUP, INC | 100.00 +— (+0.0%) | 140.00 -56.0 (-28.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.80 -50.0% | 6 qtrs — |
| 22 | TOWER RESEARCH CAPITAL LLC (TRC) | 88.00 -4.1K (-97.9%) | 123.00 -8.0K (-98.5%) | 0.00% -0.013 pp | 0.00% 0.000 pp | USD1.91 -26.7% | 3 qtrs — |
| 23 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 25.00 +25.0 (+100.0%) | 35.00 +35.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.40 +0.0% | 1 qtrs NEW |
| 24 | BANK OF AMERICA CORP /DE/ | 23.00 +23.0 (+100.0%) | 32.00 +32.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.39 +0.7% | 1 qtrs NEW |
| 25 | TWO SIGMA SECURITIES, LLC | — -10.2K (-100.0%) | — -20.1K (-100.0%) | 0.00% -0.032 pp | 0.00% -0.003 pp | USD— | 2 qtrs SOLD |
| 26 | GROUND SWELL CAPITAL, LLC | — -20.5K (-100.0%) | — -40.1K (-100.0%) | 0.00% -0.064 pp | 0.00% -0.088 pp | USD— | 2 qtrs SOLD |
| 27 | SANDERS MORRIS HARRIS LLC | — -12.0K (-100.0%) | — -23.5K (-100.0%) | 0.00% -0.038 pp | 0.00% -0.003 pp | USD— | 2 qtrs SOLD |
| 28 | VIRTU FINANCIAL LLC | — -75.8K (-100.0%) | — -149.0K (-100.0%) | 0.00% -0.237 pp | 0.00% -0.008 pp | USD— | 3 qtrs SOLD |
| 29 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | — -15.0K (-100.0%) | — -29.3K (-100.0%) | 0.00% -0.047 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 30 | JPMORGAN CHASE & CO | — -13.0 (-100.0%) | — -25.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 185.5K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 626.3K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 676.49 | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 1.9K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 137.20 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 317.4K | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 695.78 | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 378.43 | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 152.78 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 16.84 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
3
Shares acquired
—
Shares disposed
142.0K
Cash buys
—
Cash sales
3.00
Net activity
-142,012
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-22 | Search Theodore F. | Director | A-Award | A | Stock options (right to buy) | 50,000 | 1.34 | 67.0K | 50,000 | D | ↗ |
| 2026-01-22 | Romness Paul A. | Director / Officer | A-Award | A | Stock options (right to buy) | 1,000,000 | 1.34 | 1.34M | 1,000,000 | D | ↗ |
| 2026-01-22 | PETIT ROBERT | Officer | A-Award | A | Stock options (right to buy) | 100,000 | 1.34 | 134.0K | 100,000 | D | ↗ |
| 2026-01-22 | McKean-Dieser Avril Suzette | Director | A-Award | A | Stock options (right to buy) | 50,000 | 1.34 | 67.0K | 50,000 | D | ↗ |
| 2026-01-22 | Jarry Olivier Roger | Director | A-Award | A | Stock options (right to buy) | 50,000 | 1.34 | 67.0K | 50,000 | D | ↗ |
| 2026-01-22 | Galzahr Karim | Director | A-Award | A | Stock options (right to buy) | 50,000 | 1.34 | 67.0K | 50,000 | D | ↗ |
| 2026-01-22 | Ciccio John | Director | A-Award | A | Stock options (right to buy) | 50,000 | 1.34 | 67.0K | 50,000 | D | ↗ |
| 2026-01-22 | Acevedo Christopher P. | Officer | A-Award | A | Stock options (right to buy) | 100,000 | 1.34 | 134.0K | 100,000 | D | ↗ |
| 2025-10-21 | Search Theodore F. | Director | A-Award | A | Stock options (right to buy) | 140,000 | 1.80 | 252.0K | 140,000 | D | ↗ |
| 2025-10-21 | Romness Paul A. | Director / Officer | A-Award | A | Stock options (right to buy) | 1,950,000 | 1.80 | 3.51M | 1,950,000 | D | ↗ |
| 2025-10-21 | PETIT ROBERT | Officer | A-Award | A | Stock options (right to buy) | 500,000 | 1.80 | 900.0K | 500,000 | D | ↗ |
| 2025-10-21 | McKean-Dieser Avril Suzette | Director | A-Award | A | Stock options (right to buy) | 140,000 | 1.80 | 252.0K | 140,000 | D | ↗ |
| 2025-10-21 | Jarry Olivier Roger | Director | A-Award | A | Stock options (right to buy) | 140,000 | 1.80 | 252.0K | 140,000 | D | ↗ |
| 2025-10-21 | Galzahr Karim | Director | A-Award | A | Stock options (right to buy) | 140,000 | 1.80 | 252.0K | 140,000 | D | ↗ |
| 2025-10-21 | Ciccio John | Director | A-Award | A | Stock options (right to buy) | 140,000 | 1.80 | 252.0K | 140,000 | D | ↗ |
| 2025-10-21 | Acevedo Christopher P. | Officer | A-Award | A | Stock options (right to buy) | 200,000 | 1.80 | 360.0K | 200,000 | D | ↗ |
| 2025-05-09 | Auerbach Shalom | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-05-07 | Auerbach Shalom | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 82,000 | 2.00 | 163.9K | 2,664,199 | I | ↗ |
| 2025-04-10 | Auerbach Shalom | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 10,000 | 1.39 | 13.9K | 2,746,199 | I | ↗ |
| 2025-04-09 | Auerbach Shalom | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 50,012 | 1.35 | 67.7K | 2,756,199 | I | ↗ |
| 2025-02-28 | Romness Paul A. | Director / Officer / 10% Owner | J-Other | A | Common Stock, par value $0.001 per share | 225,000 | 0.00 | — | 2,473,000 | D | ↗ |
| 2025-02-27 | Auerbach Shalom | 10% Owner | J-Other | D | Common Stock, par value $0.001 per share | 225,000 | 1.64 | 369.0K | 2,806,211 | I | ↗ |
| 2025-02-14 | Auerbach Shalom | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 100,000 | 2.84 | 284.3K | 2,431,211 | I | ↗ |
| 2025-01-28 | Galzahr Karim | Director | — | — | Stock options (right to buy) | 40,000 | 1.86 | 74.4K | 0 | D | ↗ |
| 2025-01-15 | Auerbach Shalom | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 16,720 | 6.74 | 112.6K | 2,531,211 | I | ↗ |
| 2024-12-31 | Search Theodore F. | Director | — | — | Common Stock | 0 | 0.00 | — | 435,835 | I | ↗ |
| 2024-12-31 | Romness Paul A. | Director / Officer / 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 2,248,000 | D | ↗ |
| 2024-12-31 | McKean-Dieser Avril Suzette | Director | — | — | Common Stock | 0 | 0.00 | — | 5,000 | D | ↗ |
| 2024-12-31 | GODDARD COLIN | Director | — | — | Common Stock | 0 | 0.00 | — | 26,250 | D | ↗ |
| 2024-12-31 | Ciccio John | Director | — | — | Common Stock | 0 | 0.00 | — | 20,000 | D | ↗ |
| 2024-12-31 | Acevedo Christopher P. | Officer | — | — | Common Stock | 0 | 0.00 | — | 100,000 | D | ↗ |
| 2024-12-05 | Search Theodore F. | Director | A-Award | A | Non-qualified stock options (right to buy) | 40,000 | 1.86 | 74.4K | 40,000 | D | ↗ |
| 2024-12-05 | Romness Paul A. | Director / Officer / 10% Owner | A-Award | A | Non-qualified stock options (right to buy) | 800,000 | 1.86 | 1.49M | 800,000 | D | ↗ |
| 2024-12-05 | McKean-Dieser Avril Suzette | Director | A-Award | A | Non-qualified stock options (right to buy) | 40,000 | 1.86 | 74.4K | 40,000 | D | ↗ |
| 2024-12-05 | Jarry Olivier Roger | Director | A-Award | A | Non-qualified stock options (right to buy) | 40,000 | 1.86 | 74.4K | 40,000 | D | ↗ |
| 2024-12-05 | GODDARD COLIN | Director | A-Award | A | Non-qualified stock options (right to buy) | 400,000 | 1.86 | 744.0K | 400,000 | D | ↗ |
| 2024-12-05 | Ciccio John | Director | A-Award | A | Non-qualified stock options (right to buy) | 40,000 | 1.86 | 74.4K | 40,000 | D | ↗ |
| 2024-12-05 | Acevedo Christopher P. | Officer | A-Award | A | Non-qualified stock options (right to buy) | 200,000 | 1.86 | 372.0K | 200,000 | D | ↗ |
| 2024-10-28 | McKean-Dieser Avril Suzette | Director | — | — | Common stock, par value $0.001 per share | 0 | 0.00 | — | 5,000 | D | ↗ |
| 2024-10-28 | Jarry Olivier Roger | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-02 | Search Theodore F. | Director | C-Conversion | A | Common stock, par value $0.001 per share ("Common Stock") | 101,765 | 25,000.00 | 2.54B | 139,265 | — | ↗ |
| 2024-08-02 | Ciccio John | Director | C-Conversion | A | Common Stock | 30,264 | 50,000.00 | 1.51B | 435,835 | — | ↗ |
| 2024-08-02 | Auerbach Shalom | 10% Owner | C-Conversion | A | Common Stock, par value $0.001 per share | 633,980 | 0.00 | — | 1,438,355 | I | ↗ |
| 2024-07-31 | Search Theodore F. | Director | — | I | Common Stock | 0 | 0.00 | — | 37,500 | — | ↗ |
| 2024-07-31 | Romness Paul A. | Director / Officer / 10% Owner | — | D | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 2,248,000 | — | ↗ |
| 2024-07-31 | PETIT ROBERT | Officer | — | D | Common stock, par value $0.001 per share | 0 | 0.00 | — | 200,000 | — | ↗ |
| 2024-07-31 | GODDARD COLIN | Director | — | D | Common stock, par value $0.001 per share ("Common Stock") | 0 | 0.00 | — | 26,250 | — | ↗ |
| 2024-07-31 | Ciccio John | Director | — | I | Common Stock | 0 | 0.00 | — | 37,500 | — | ↗ |
| 2024-07-31 | Borg Joacim | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-07-31 | Auerbach Shalom | 10% Owner | — | — | Convertible Promissory Note | 0 | 0.00 | — | 0 | I | ↗ |
| 2024-07-31 | Acevedo Christopher P. | Officer | — | D | Common stock, par value $0.001 per share | 0 | 0.00 | — | 100,000 | — | ↗ |
| 2003-06-30 | BOLOGNA THOMAS A | Director / Officer | D-Return | D | Option (Right to Buy) 01/18/01 | 200,000 | 1.56 | 312.0K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
42.04M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Paul A. Romness, MPH President and Chief Executive Officer | 480.0K | 200.0K | — | 2.75M | — | — | 3.43M | 80.20% | ↗ |
| 2 | 2024 | Robert G. Petit, Ph.D. Chief Medical and Scientific Officer | 420.0K | — | — | 245.0K | — | — | 665.0K | 36.85% | ↗ |
| 3 | 2024 | Christopher Acevedo Chief Financial Officer | 36.0K | — | — | 122.5K | — | — | 158.5K | 77.29% | ↗ |
| 4 | 2023 | Paul A. Romness, MPH President and Chief Executive Officer | 360.0K | — | — | — | — | — | 360.0K | 0.00% | ↗ |
| 5 | 2023 | Robert G. Petit, Ph.D. Chief Medical and Scientific Officer | 300.0K | — | — | — | — | — | 300.0K | 0.00% | ↗ |
| 6 | 2023 | Christopher Acevedo Chief Financial Officer | 36.0K | — | — | — | — | — | 36.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Paul A. Romness | Founder, Chairman, President & Chief Executive Officer | 722.2K | male |
| Robert G. Petit | Chief Medical Officer & Chief Scientific Officer | 420.0K | — |
| Christopher Acevedo | Chief Financial Officer | 36.0K | male |
| Gerald E. Commissiong | Chief Business Officer | — | male |
| Jack Doll | Chief of Staff | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OSTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
